Physician profile
Virginia M Factor
NPI 1376841635
$6,674.59
in general payments reported to CMS, 2019-2025
46 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $294 · 2022: $882 · 2023: $1,380 · 2024: $1,094 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.80 | 2022-2025 | |
| Lilly USA, LLC | $576.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $568.15 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $543.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $473.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.23 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $393.84 | 2019-2025 | |
| Amgen INC. | $228.76 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.11 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $203.36 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $203.04 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Sumitomo Pharma America, INC. | $200.11 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $184.90 | 2022-2025 | |
| Allergan, INC. | $181.06 | 2019-2020 | |
| Astellas Pharma US INC | $167.82 | 2019-2024 | Veozah, Myrbetriq |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Factor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.